Exploration of cannabis use and polygenic risk scores on the psychotic symptom progression of a FEP cohort
Segura, A. G ; Mané, A. ; Prohens, Ll. ; Rodríguez, N. ; Mezquida, G. ; Cuesta, M. J ; Vieta, E. ; Amoretti, S. ; Lobo, A. (Universidad de Zaragoza) ; González-Pinto, A. ; Díaz-Caneja, C. M. ; Roldán Bejarano, A. ; Jiménez, E. ; Baeza, I. ; Legido, T. ; Saiz-Ruiz, J. ; Bernardo, M. ; Mas, S. ; PEPs Group
Resumen: Cannabis use is highly prevalent in first-episode psychosis (FEP) and plays a critical role in its onset and prognosis, but the genetic underpinnings promoting both conditions are poorly understood. Current treatment strategies for cannabis cessation in FEP are clearly inefficacious. Here, we aimed to characterize the association between cannabis-related polygenic risk scores (PRS) on cannabis use and clinical course after a FEP. A cohort of 249 FEP individuals were evaluated during 12 months. Symptom severity was measured with the Positive and Negative Severity Scale and cannabis use with the EuropASI scale. Individual PRS for lifetime cannabis initiation (PRSCI) and cannabis use disorder (PRSCUD) were constructed. Current cannabis use was associated with increased positive symptoms. Cannabis initiation at younger ages conditioned the 12-month symptom progression. FEP patients with higher cannabis PRSCUD reported increased baseline cannabis use. PRSCI was associated with the course of negative and general symptomatology over follow-up. Cannabis use and symptom progression after a FEP were modulated by cannabis PRS, suggesting that lifetime initiation and use disorders may have partially independent genetic factors. These exploratory results may be the first step to identify those FEP patients more vulnerable to cannabis use and worse outcomes to ultimately develop tailored treatments.
Idioma: Inglés
DOI: 10.1016/j.psychres.2023.115249
Año: 2023
Publicado en: PSYCHIATRY RESEARCH 325 (2023), 115249 [7 pp.]
ISSN: 0165-1781
Factor impacto SCIMAGO: 2.189 - Psychiatry and Mental Health (Q1) - Biological Psychiatry (Q1)
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CD20-00177
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI08-0208
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI20-00661
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI11-00325
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI14-00612
Tipo y forma: Article (Published version)
Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2024-07-05-12:47:44)
Visitas y descargas
Idioma: Inglés
DOI: 10.1016/j.psychres.2023.115249
Año: 2023
Publicado en: PSYCHIATRY RESEARCH 325 (2023), 115249 [7 pp.]
ISSN: 0165-1781
Factor impacto SCIMAGO: 2.189 - Psychiatry and Mental Health (Q1) - Biological Psychiatry (Q1)
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/CD20-00177
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI08-0208
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI20-00661
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI11-00325
Financiación: info:eu-repo/grantAgreement/ES/MINECO/PI14-00612
Tipo y forma: Article (Published version)
Área (Departamento): Area Psiquiatría (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2024-07-05-12:47:44)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2023-08-30, last modified 2024-07-05